CA2720621A1 - Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation d'erk1/erk2, biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb) - Google Patents

Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation d'erk1/erk2, biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb) Download PDF

Info

Publication number
CA2720621A1
CA2720621A1 CA2720621A CA2720621A CA2720621A1 CA 2720621 A1 CA2720621 A1 CA 2720621A1 CA 2720621 A CA2720621 A CA 2720621A CA 2720621 A CA2720621 A CA 2720621A CA 2720621 A1 CA2720621 A1 CA 2720621A1
Authority
CA
Canada
Prior art keywords
disease
alzheimer
cells
specific molecular
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2720621A
Other languages
English (en)
Inventor
Tapan Kumar Khan
Daniel L. Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/078,857 external-priority patent/US20080221042A1/en
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Publication of CA2720621A1 publication Critical patent/CA2720621A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2720621A 2008-04-07 2009-04-03 Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation d'erk1/erk2, biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb) Abandoned CA2720621A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/078,857 US20080221042A1 (en) 2005-10-11 2008-04-07 Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
US12/078,857 2008-04-07
PCT/US2009/002120 WO2009126232A1 (fr) 2008-04-07 2009-04-03 Modifications spécifiques de la maladie d'alzheimer du rapport de phosphorylation d’erk1/erk2, biomarqueurs moléculaires spécifiques de la maladie d’alzheimer (adsmb)

Publications (1)

Publication Number Publication Date
CA2720621A1 true CA2720621A1 (fr) 2009-10-15

Family

ID=41037627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720621A Abandoned CA2720621A1 (fr) 2008-04-07 2009-04-03 Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation d'erk1/erk2, biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb)

Country Status (9)

Country Link
EP (1) EP2263090A1 (fr)
JP (1) JP2011516883A (fr)
KR (1) KR20100132997A (fr)
AU (1) AU2009234405A1 (fr)
BR (1) BRPI0911073A2 (fr)
CA (1) CA2720621A1 (fr)
IL (1) IL208296A0 (fr)
TW (1) TW200942819A (fr)
WO (1) WO2009126232A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935266C (fr) * 2014-01-03 2022-02-01 Blanchette Rockefeller Neurosciences Institute Convergence du taux d'agregation associes a des diagnostics peripheriques valides de la maladie d'alzheimer
EP3600027A4 (fr) 2017-03-31 2020-12-23 Neurodiagnostics LLC Test morphométrique basé sur les lymphocytes dédié à la maladie d'alzheimer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043998A1 (fr) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation erk1/erk2

Also Published As

Publication number Publication date
TW200942819A (en) 2009-10-16
JP2011516883A (ja) 2011-05-26
KR20100132997A (ko) 2010-12-20
IL208296A0 (en) 2010-12-30
WO2009126232A1 (fr) 2009-10-15
EP2263090A1 (fr) 2010-12-22
BRPI0911073A2 (pt) 2019-09-24
AU2009234405A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
US20180024146A1 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US9797913B2 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (ADSMB)
US7595167B2 (en) Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
EP1934618B1 (fr) Modifications du taux de phosphorylation d'erk1/erk2 specifiques de la maladie d'alzheimer relativement aux biomarqueurs moleculaires specifiques de la maladie d'alzheimer
WO2007043998A1 (fr) Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation erk1/erk2
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
JP2008520203A (ja) アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
EP1233979A1 (fr) Procede de diagnostic de maladies neurodegeneratives
CA2720621A1 (fr) Modifications specifiques de la maladie d'alzheimer du rapport de phosphorylation d'erk1/erk2, biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb)
US20080221042A1 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
Caltagarone Differential localization of Hic-5 and paxillin in the brain of Alzheimer's disease subjects
KR20070084247A (ko) 알츠하이머 질환의 진단 및 치료를 위한 포스파타제 2ａ(ｐｐ2ａ)의 비정상

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130403